Enanta Pharmaceuticals Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the discovery and development of small molecule therapeutics for viral infections and liver diseases. The company boasts a strong pipeline featuring innovative candidates targeting hepatitis B and other viral pathogens, which highlights its commitment to tackling critical healthcare issues. Enanta’s strategic emphasis on proprietary programs not only positions it as a key player in the management of infectious diseases and liver health but also has the potential to significantly enhance treatment options and improve outcomes for patients facing these substantial health challenges. Show more

Location: 4 KINGSBURY AVENUE, WATERTOWN, MA, UNITED STATES, 02472, Watertown, MA, 02472, USA | Website: https://www.enanta.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

374.3M

52 Wk Range

$4.09 - $17.15

Previous Close

$12.90

Open

$12.83

Volume

208,748

Day Range

$12.45 - $12.98

Enterprise Value

384.5M

Cash

32.3M

Avg Qtr Burn

-6.489M

Insider Ownership

4.68%

Institutional Own.

71.08%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MAVYRET (Glecaprevir) Details HCV (Hepatitis C Virus)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zelicapavir (EDP-938) Details Respiratory syncytial virus (RSV)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDP-235 Details Viral infection, COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDP-323 Details Respiratory syncytial virus (RSV)	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPS-3903 (STAT6 Inhibitor) Details Type 2 Immune-Driven Diseases	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDP-978 (KIT Inhibitor) Details Chronic Spontaneous Urticaria	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDP-514 (HBV Core inhibitor) Details Hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDP-305 (FXR Agonist) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ENP-297 (FXR inhibitor) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.